UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

Annals of oncology, 2018-10, Vol.29, p.viii362-viii363

2018

Volltextzugriff (PDF)

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29, p.viii654-viii654

2018

Volltextzugriff (PDF)

365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial

European journal of cancer (1990), 2015-09, Vol.51, p.S75-S76

2015

Volltextzugriff (PDF)

1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in

Annals of oncology, 2022-09, Vol.33, p.S1248-S1249

2022

Volltextzugriff (PDF)

1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250

Annals of oncology, 2021-09, Vol.32, p.S1171-S1171

2021

Volltextzugriff (PDF)

1014PDPhase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

P-118 Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial

Annals of oncology, 2015-06, Vol.26, p.iv34

2015

Volltextzugriff (PDF)

Phase Ib/Ii, Multicenter, Single-Arm Trial of the Oral C-Met Inhibitor Msc2156119J As Monotherapy in Patients with Met-Positive Advanced Hepatocellular Carcinoma with Child-Pugh Class a Liver Function Who Failed Sorafenib Treatment

Annals of oncology, 2014-09, Vol.25, p.iv251

2014

Volltextzugriff (PDF)

745TiPPHASE IB/II, MULTICENTER, SINGLE-ARM TRIAL OF THE ORAL C-MET INHIBITOR MSC2156119J AS MONOTHERAPY IN PATIENTS WITH MET-POSITIVE ADVANCED HEPATOCELLULAR CARCINOMA WITH CHILD-PUGH CLASS A LIVER FUNCTION WHO FAILED SORAFENIB TREATMENT

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv251-iv251

2014

Volltextzugriff (PDF)

104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies

ESMO open, 2024-03, Vol.9, p.102683, Article 102683

2024

Volltextzugriff (PDF)

1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Multimodale Therapie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten

Schmerz (Berlin, Germany), 2017-06, Vol.31 (3), p.285-288

2017

Volltextzugriff (PDF)

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

Clinical cancer research, 2024-02, Vol.30 (4), p.695-702

2024

Volltextzugriff (PDF)

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS144-TPS144

2021

Volltextzugriff (PDF)

Ist eine Team-basierte rheumatologische Versorgung mit Delegation an die Fachassistenz der Standardversorgung ebenbürtig oder sogar überlegen? – Das StärkeR-Projekt

Zeitschrift für Rheumatologie, 2020-10, Vol.79 (Suppl 2), p.52-54

2020

Volltextzugriff (PDF)

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS4117-TPS4117

2020

Volltextzugriff (PDF)

Multimodal therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles

Schmerz (Berlin, Germany), 2017-06, Vol.31 (3), p.285-288

2017

Volltextzugriff (PDF)

FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.648

2015

Volltextzugriff (PDF)

Is team-based rheumatological care with delegation to specialised nurses equal to or even superior to standard care?-the StärkeR project

Zeitschrift für Rheumatologie, 2020-10, Vol.79 (Suppl 2), p.52-54

2020

Volltextzugriff (PDF)

FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis: Table 1

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.648-648

2015

Volltextzugriff (PDF)

Evaluation of different approaches for road course estimation using imaging radar

2011 IEEE/RSJ International Conference on Intelligent Robots and Systems, 2011, p.4587-4592

2011

Volltextzugriff (PDF)

OpenMP on Multicore Architectures

A Practical Programming Model for the Multi-Core Era, p.54-64

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(20)
Tagungsberichte
(2)

Sprache

Englisch
(18)
Deutsch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial

1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in

1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250

1014PDPhase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

P-118 Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial

Phase Ib/Ii, Multicenter, Single-Arm Trial of the Oral C-Met Inhibitor Msc2156119J As Monotherapy in Patients with Met-Positive Advanced Hepatocellular Carcinoma with Child-Pugh Class a Liver Function Who Failed Sorafenib Treatment

745TiPPHASE IB/II, MULTICENTER, SINGLE-ARM TRIAL OF THE ORAL C-MET INHIBITOR MSC2156119J AS MONOTHERAPY IN PATIENTS WITH MET-POSITIVE ADVANCED HEPATOCELLULAR CARCINOMA WITH CHILD-PUGH CLASS A LIVER FUNCTION WHO FAILED SORAFENIB TREATMENT

104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies

1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Multimodale Therapie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer

Ist eine Team-basierte rheumatologische Versorgung mit Delegation an die Fachassistenz der Standardversorgung ebenbürtig oder sogar überlegen? – Das StärkeR-Projekt

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer

Multimodal therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles

FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis

Is team-based rheumatological care with delegation to specialised nurses equal to or even superior to standard care?-the StärkeR project

FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis: Table 1

Evaluation of different approaches for road course estimation using imaging radar

OpenMP on Multicore Architectures

Suchergebnisse filtern